Neurocrine Biosciences (NBIX) Goodwill (2022 - 2026)

Neurocrine Biosciences (NBIX) has reported Goodwill for 5 consecutive years, with $500.6 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Goodwill changed N/A year-over-year to $500.6 million; the trailing twelve-month figure through Jun 2026 stood at $500.6 million (changed N/A YoY), and the FY2025 full-year result was $6.1 million, up 7.02% from the prior year.
• Goodwill rose to $500.6 million in Q2 2026 per NBIX's latest filing, from $6.0 million in the prior quarter.
• Across five years, Goodwill topped out at $500.6 million in Q2 2026 and bottomed at $5.4 million in Q4 2022.
• Historically, Goodwill has averaged $47.0 million across 5 years, with a median of $5.7 million in 2023.
• The widest YoY moves for Goodwill: up 10.91% in 2024, down 1.72% in 2024.
• Over 5 years, Goodwill stood at $5.4 million in 2022, then advanced by 7.41% to $5.8 million in 2023, then retreated by 1.72% to $5.7 million in 2024, then advanced by 7.02% to $6.1 million in 2025, then surged by 8106.56% to $500.6 million in 2026.
• According to Business Quant data, Goodwill over the past three periods registered $500.6 million, $6.0 million, and $6.1 million for Q2 2026, Q1 2026, and Q4 2025 respectively.